Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study

M. B. Jensen*, C. B. Pedersen, M. A. Misiakou, M. L.M. Talman, L. Gibson, U. B. Tange, H. Kledal, I. Vejborg, N. Kroman, F. C. Nielsen, B. Ejlertsen, M. Rossing

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

31 Downloads (Pure)

Abstract

Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.

Original languageEnglish
Article number47
Journalnpj Breast Cancer
Volume9
Issue number1
Number of pages8
ISSN2374-4677
DOIs
Publication statusPublished - 2023

Fingerprint

Dive into the research topics of 'Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study'. Together they form a unique fingerprint.

Cite this